---
document_datetime: 2025-12-09 10:35:48
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/levetiracetam-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: levetiracetam-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.2893376
conversion_datetime: 2025-12-20 18:01:13.769843
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Levetiracetam Accord

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number     | Scope                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                            |
|------------------------|-------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------------|
| Variation type IA_IN / | C.I.3 Change(s) in the Summary of Product | 09/12/2025                          |                                             | SmPC and PL                      | To update Section 4.6 of the SmPC and Section 2 of |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000316836                     | Characteristics, Labelling or Package Leaflet of human medicinal products intended to implement the outcome of a procedure concerning PSUR or PASS, or the outcome of the assessment done by the competent authority under Articles 45 or 46 of Regulation 1901/2006 - C.I.3.a Implementation of wording agreed by the competent authority - Accepted   |            |     | the PL to implement the wording agreed by the PRAC with information on the risk of neurodevelopmental disorders in children exposed prenatally to levetiracetam, following the outcome of the PSUSA procedure (PSUSA/00001846/202411) for levetiracetam.   |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IA / EMA/VR/0000314020 | B.II.b.4 Change in the batch size (including batch size ranges) of the finished product - B.II.b.4.a Increase of the batch size up to 10-fold for the pharmaceutical form medicinal gas - Accepted                                                                                                                                                      | 02/12/2025 | N/A |                                                                                                                                                                                                                                                            |
| Variation type IA / EMA/VR/0000314016 | B.II.b.4 Change in the batch size (including batch size ranges) of the finished product - B.II.b.4.a Increase of the batch size up to 10-fold for the pharmaceutical form medicinal gas - Accepted                                                                                                                                                      | 25/11/2025 | N/A |                                                                                                                                                                                                                                                            |
| Variation type IB / EMA/VR/0000281555 | B.II.d.1 Change in the specification parameters and/or limits of the finished product - B.II.d.1.d Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter such as odour and taste or identification test for a colouring or flavouring material) - Accepted                                                     | 14/07/2025 | N/A |                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000268045   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Other RMP changes (e.g. agreed wording + template change) - Accepted C.I.11.z - To update Risk Management Plan (v7.0) for Levetiracetam Accord to update safety concerns in line with EPAR for Risk- management-plan of reference product Keppra (Version 10.2, dated 07-Oct-2024)   | 10/07/2025   | N/A   |
|-----------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
| Variation type IA / EMA/VR/0000280189   | B.II.d.1 Change in the specification parameters and/or limits of the finished product - B.II.d.1.d Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter such as odour and taste or identification test for a colouring or flavouring material) - Refused                                                                                                                                                                                                                                                                                     | 23/06/2025   | N/A   |
| Variation type IB / EMA/VR/0000263132   | This was an application for a group of variations. B.III.1.a European Pharmacopoeial Certificate of Suitability to the relevant Ph.                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 16/06/2025   | N/A   |

<div style=\"page-break-after: always\"></div>

| Eur. Monograph - B.III.1.a.2 Updated certificate from an already approved manufacturer - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate reagent used in the manufacturing process of the active substance - B.I.b.1.c Addition of a new specification parameter to the   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                          | method - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |     |                 |                                                                                                                                                                                                                                                                             |
|------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000265690    | C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a - To update section 4.8 of the SmPC and section 4 of the Package Leaflet to include additional information on signs and symptoms of Drug Reactions with Eosinophilia and Systemic Symptoms (DRESS), following assessment of the same change for the reference product Keppra. Additionally, the MAH has taken the opportunity to make minor editorial revisions | 30/04/2025 |     | SmPC and PL     | To update section 4.8 of the SmPC and section 4 of the Package Leaflet to include additional information on signs and symptoms of Drug Reactions with Eosinophilia and Systemic Symptoms (DRESS), following assessment of the same change for the reference product Keppra. |
| Variation type IA / EMA/VR/0000248590    | B.III.1.a European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - B.III.1.a.2 Updated certificate from an already approved manufacturer - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 12/02/2025 | N/A |                 |                                                                                                                                                                                                                                                                             |
| Variation type IA_IN / EMA/VR/0000234941 | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 21/11/2024 |     | Annex II and PL |                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

| B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.2 Including batch control/testing - Accepted B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|